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Abstract Induction of HIF-1α by oxygen limitation
promotes increased phosphorylation and catalytic depression
of mitochondrial pyruvate dehydrogenase (PDH) and an
enhanced glycolytic poise in cells. Cobalt chloride and
desferrioxamine are widely used as mimics for hypoxia
because they increase the levels of HIF-1α. We evaluated the
ability of these agents to elicit selected physiological
responses to hypoxia as a means to metabolically precondition
mammalian cells, but without the detrimental effects of
hypoxia. We show that, while CoCl2 does increase HIF-1α in
a dose-dependent manner, it unexpectedly and strikingly
decreases PDH phosphorylation at E1α sites 1, 2, and 3
(Ser293, Ser300, and Ser232, respectively) in HepG2 cells. This
same effect is also observed for site 1 in mouse NIH/3T3
fibroblasts and J774 macrophages. CoCl2 unexpectedly
decreases the mRNA expression for PDH kinase-2 in HepG2
cells, which likely explains the dephosphorylation of PDH
observed. And nor does desferrioxamine promote the
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expected increase in PDH phosphorylation. Dimethyloxaloylglycine (a prolyl hydroxylase inhibitor) performs better in this
regard, but failed to promote the stronger effects seen with
hypoxia. Consequently, CoCl2 and desferrioxamine are
unreliable mimics of hypoxia for physiological events
downstream of HIF-1α stabilization. Our study demonstrates
that mimetic chemicals must be chosen with caution and
evaluated thoroughly if bona fide cellular outcomes are to be
promoted with fidelity.
Keywords Metabolic preconditioning . Hypoxia inducible
factor 1 . Cobalt chloride . Desferrioxamine . Pyruvate
dehydrogenase . Cell Culture (human, mouse)

Introduction
The metabolic preconditioning of mammalian tissue has
become a significant topic of research in recent years
(Menze et al. 2005; Gohil et al. 2010; Halestrap 2010;
Menze et al. 2010; Gohil et al. 2011; Hand et al. 2011a).
For example, the physiological response to hypoxia has
been shown to have beneficial effects for biostabilization
during ischemic recovery (Alchera et al. 2010; Hyvärinen et
al. 2010; Semenza 2011; Eckle et al. 2012; Sarkar et al.
2012). However, exposure to natural hypoxia can result in
harmful oxidative stress and reduced viability in most
mammalian cells. Therefore, in lieu of true oxygen
limitation, artificial alternatives that induce a bona fide
physiological hypoxic response would be desirable. For
some time, it has been suggested that CoCl2 may act as
an artificial mimic of hypoxia (Goldwasser et al. 1958;
Goldberg et al. 1987, 1988; Bunn and Poyton 1996).
CoCl2 may replace the necessary ferrous iron of prolyl
hydroxylase (PHD) and prevent it from targeting hypoxia

Cell Tissue Res

inducible factor-1α (HIF-1α; Semenza and Wang 1992) for
proteasomal degradation (Ivan et al. 2001; Jaakkola et al.
2001). Consequently, CoCl2 has been used as an artificial
stabilizer of HIF-1α (Wang and Semenza 1993a, b; Pugh et
al. 1997; Kim et al. 2006). During the natural state of hypoxia,
oxygen limitation (and/or an associated elevation of reactive
oxygen species) (Brunelle et al. 2005; Guzy et al. 2005;
Semenza 2007; Kaelin and Ratcliffe 2008; Ježek et al. 2010)
inactivates PHD, and the cellular concentrations of HIF-1α
increase (Jiang et al. 1996; Ivan et al. 2001; Jaakkola et
al. 2001; Semenza 2007; Kaelin and Ratcliffe 2008;
Ježek et al. 2010). HIF-1 then promotes expression of
numerous downstream target genes, including those
whose products phosphorylate and downregulate the
activity of the pyruvate dehydrogenase complex (PDC)
(Kim et al. 2006; Papandreou et al. 2006; Semenza
2007; Lu et al. 2008). Although CoCl2 does increase
the cellular levels of HIF-1α, the downstream effects of this
commonly utilized mimic of hypoxia have been incompletely
evaluated. Because inhibition of PDC is key to the depression
of mitochondrial oxidative metabolism under hypoxia (Kim et
al. 2006; Papandreou et al. 2006; Ježek et al. 2010), it is
important that CoCl2 elicits a comparable increase in PDC
phosphorylation in order to emulate hypoxia in a physiologically valid manner. Thus, we evaluate here the impact of three
reported PHD inhibitors [CoCl2, desferrioxamine, dimethyloxaloylglycine (DMOG)] on HIF-1α stabilization and PDC
phosphorylation in three mammalian cell lines.
The PDC is strongly regulated by the phosphorylation
and de-phosphorylation of its pyruvate dehydrogenase
(PDH) component, also known simply as E1 (Korotchkina
and Patel 2001; Harris et al. 2002). In humans, there are four
isozymes of the pyruvate dehydrogenase kinase (PDK1-4)
and two isozymes of the pyruvate dehydrogenase phosphatase (PDP1-2), which are integral components of the PDC
and are synthesized in a tissue-dependent manner (BowkerKinley et al. 1998; Korotchkina and Patel 2001; Harris et al.
2002; Kim et al. 2006; Papandreou et al. 2006). PDH is an
α2β2 tetramer, and there are three phosphorylation sites on
the α subunit: Ser293, Ser300, and Ser232 (sites 1, 2, and 3,
respectively) (Korotchkina and Patel 2001). These sites are
differentially affected by the different isoforms of PDK and
PDP, but phosphorylation at any of these sites will lower
PDC activity (Korotchkina and Patel 2001).
We show that CoCl2, desferrioxamine, and DMOG all
increase HIF-1α to varying degrees. However, in contrast to
hypoxia, CoCl2 promotes a marked decrease in PDH
phosphorylation in all three cell lines tested—human HepG2
hepatoma cells, NIH/3T3 mouse fibroblasts, and J774 mouse
macrophages. Enhancement of PDH phosphorylation was
minimal at best with desferrioxamine even though it also
elevated HIF-1α. DMOG increased phosphorylation for all
3 sites in HepG2 cells, but not to the extent seen with hypoxia.

CoCl2 and desferrioxamine do not serve as reliable mimics of
hypoxia in terms of their influence on some targets
downstream of HIF-1, and thus should be used with
caution if bona fide physiological impacts are desired
beyond HIF-1α stabilization.

Materials and methods
Cell culture
All three cell lines were obtained from ATCC (Manassas,
VA, USA). HepG2 human hepatoma cells, NIH/3T3 mouse
fibroblasts, and J774 mouse macrophages were maintained in
Gibco Minimum Essential Medium (MEM) supplemented
with 10 % fetal bovine serum (FBS), 100 U/ml penicillin,
100 μg/ml streptomycin, and 2 mM glutamine (all from
Invitrogen, Carlsbad, CA, USA). Cells were grown to 70 %
confluence in 75 cm2 tissue culture flasks (Celltreat, Shirley,
MA, USA) and maintained in a humidified atmosphere of 5 %
CO2–95 % air at 37 °C. For experiments, cells were detached
using 0.25 % trypsin-EDTA solution (Invitrogen) and seeded
at 1–3×106 cells/plate. The number of cells was determined
by counting with a hemocytometer (Hausser and Son,
Philadelphia, PA, USA).
For hypoxia studies, cell culture dishes were transferred to a
modular incubator chamber (Model MIC-101; BillupsRothenberg, Del Mar, CA, USA) and exposed to a gas mixture
composed of 1 % oxygen, 5 % carbon dioxide, and 94 %
nitrogen (premixed gas obtained from Airgas Southwest, The
Woodlands, TX, USA). The chamber containing culture plates
was flushed with the above gas mixture for 30 min at a flow
rate of 9.5 L/min and incubated for 3 h at 37 °C to allow
equilibration of culture medium with the gas phase. The chamber was flushed again for 30 min and then the cells incubated
for 21 h at 37 °C. For CoCl2 and desferrioxamine studies, cells
were exposed to the indicated concentrations for 24 h at 37 °C.
Western blotting
Treated cells were harvested directly in SDS-PAGE buffer
(Laemmli) composed of 62.5 mmol·l−1 TRIS–HCl pH 6.8,
2 % SDS, 25 % glycerol, and 5 % β-mercaptoethanol.
Protein concentrations were quantified using Pierce
660 nm reagent with the ionic detergent compatibility
reagent added per the manufacturer’s instructions (Thermo
Fisher Scientific, Rockford, IL, USA). Samples were heat
denatured for 1 min at 96 °C in sample buffer and fractionated by SDS-PAGE with 8 % polyacrylamide gels using a
Mini Protein 3 gel apparatus (Bio-Rad, Hercules, CA, USA)
at 125 V for 1 h followed by 175 V for 15 min. After
SDS-PAGE, proteins were electrophoretically transferred
to nitrocellulose (0.2 μm Trans-Blot; Bio-Rad) using a
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Bio-Rad Mini Trans-Blot transfer cell (80 V for 1 h at <18 °C).
Blots were blocked with a solution of 5 % fat-free dry milk in
TRIS-buffered saline (TBS-T; 50 mM TRIS-base, 150 mM
NaCl, 0.05 % Tween-20, pH 7.6 with HCl) and then incubated
overnight with a primary antibody at 4 °C. Antibodies used
were monoclonal anti-HIF-1α (BD Transduction Laboratories,
Sparks, MD, USA), polyclonal PhosphoDetect Anti-PDHE1α (pSer293), Anti-PDH-E1α (pSer300), and Anti-PDH-E1α
(pSer232) (Merck, Darmstadt, Germany), and polyclonal antiβ-actin (Cell Signaling Technology, Danvers, MA, USA).
Blots were subsequently washed in TBS-T and incubated for
1 h with the appropriate species-specific secondary IgG HRPlinked antibodies (Cell Signaling Technology) and visualized
with Lumiglo chemiluminescent reagent (Cell Signaling
Technology). All blotting procedures were performed at 22–
23 °C. Image J software (National Institutes of Health,
Bethesda, MD, USA) was used for quantification of Western
blot images.

smaller product optimized for rtqPCR, primers for PDK-2 were
5′-TCATCAACCAGCACACCCTCATCT-3′ and 5′-ACTTGT
CACACAGGAGCTTAGCCA-3′. The primers used for human
β-actin were 5′-GGCACCCAGCACAATGAAGATCAA-3′
and 5′-ACTCGTCATACTCCTGCTTGCTGA-3′.
Statistical analyses
One-way ANOVA was performed using SAS v.9.1 (SAS Institute, Cary, NC, USA). Assumptions of normality and homogeneity of variance were met, and a Tukey–Kramer adjustment
was used for multiple pair-wise comparisons of means. Nine
separate tests were performed, each comprised of three nested
replicates for each sample. Each experimental treatment was
compared to the control in order to obtain the percent change
(Pfaffl 2001). Values are expressed as mean ± standard deviation (S.D.). Statistical analysis of Western blot quantification
was performed with Graphpad InStat (Graphpad Software, La
Jolla, CA, USA). p≤0.05 was considered significant.

PCR and rtqPCR
RNA was isolated using an RNeasy Mini kit (Qiagen, Valencia,
CA, USA) as per the manufacturer’s instructions for animal
cells. cDNA was synthesized using a DyNAmo cDNA synthesis kit (New England Biolabs, Ipswich, MA, USA).
PCR analysis was performed using a GeneAmp PCR
System 9700 (Applied Biosystems, Carlsbad, CA, USA)
and Crimson Taq DNA polymerase mix (New England
Biolabs) as per manufacturer’s instructions. In brief, the reaction
mixture contained 1× Crimson Taq reactions buffer, 200 μM
dNTPs, 0.5 μM each primer, template cDNA, 1.25 units Taq
and was brought to a final volume of 50 μl with nuclease-free
H2O. Cycling parameters were 5 min of denaturation at 95 °C,
and then 30 cycles of a two-step protocol (95 °C, 30 s; 63 °C,
30 s), followed by a 10 min final extension step at 72 °C. PCR
products were visualized with ethidium bromide after agarose
gel electrophoresis (1.5 % SeaKem LE Agarose gel; Lonza,
Rockland, ME, USA).
rtqPCR analysis was performed with an ABI Prism 7000
(Applied Biosystems) and SYBR Green master mix (SA
Biosciences, Frederick, MD, USA) with a total reaction
volume of 25 μl. Cycling parameters were 10 min at 95 °C
and then 40 cycles of 95 °C (15 s) and 60 °C (60 s) followed
by a melting curve analysis. Each treatment was evaluated
with nine independent experiments, each with three nested
replicates, and with reference dye normalization. The
cycle threshold (Ct) value was determined with the
manufacturer’s software. After determination of the
PCR efficiencies (Pfaffl 2001), all Ct values were normalized to the expression of a bona fide housekeeping
gene, β-actin. The PCR primers used to identify human
PDK-2 were 5′-AGCCAGTTCACTGACGCCCTG-3′
and 5′-GGAGAATGAGGCTGGACTCAT-3′. To yield a

Results and discussion
CoCl2 decreases phosphorylation of pyruvate
dehydrogenase in HepG2 cells
CoCl2 is frequently used as a stabilizing agent for HIF-1α
because it inhibits the prolyl hydroxylase responsible for
signaling HIF-1α degradation (Ivan et al. 2001; Jaakkola et
al. 2001). Predictably, CoCl2 increased the levels of HIF-1α
in a dose-dependent manner in HepG2 cells when incubated
for 24 h (Fig. 1). These results are consistent with those of

Fig. 1 Western blot analysis of HepG2 cells that were incubated with
the indicated concentrations of CoCl2 or exposed to hypoxia (H; 1 %
O2) for 24 h. Amounts of HIF-1α, the phosphorylation state of PDH
site 1 (E1α subunit, phosphoserine293 ), site 2 (E1α subunit,
phosphoserine300), site 3 (E1α subunit, phosphoserine232), and
the β-actin loading control are shown

Cell Tissue Res

Wang and Semenza (1993b) for HeLa and Hep3B cells and
Pugh et al. (1997) for Hep3B cells. However, contrary to
expectations, CoCl2 strongly decreased the phosphorylation
state of PDH at site 1 (α subunit of E1, phosphoserine293)
(Fig. 1). This unexpected result was readily observed at the
low concentration of 100 μM CoCl2 after only 8 h of
incubation time (Fig. 2a). At 500 μM CoCl 2 and
above, there was no detectable phosphorylation at site
1. Similar results with CoCl2 were obtained for the
phosphorylation of PDH at site 2 (α subunit of E1,
phosphoserine300) and site 3 (α subunit of E1, phosphoserine232). Phosphorylation at both of these sites
decreased noticeably at 50–250 μM CoCl2 with the
phosphorylation at both sites completely disappearing
by 500 μM CoCl2 (Fig. 1).
As expected, exposure of HepG2 cells to hypoxia [1 %
oxygen; pO2 approximately 0.95 kPa or 7.1 mmHg (torr)] for
24 h increased the levels of HIF-1α compared to normoxic
controls (Fig. 1), although not to the extent seen with low
concentrations of CoCl2. Also as expected, hypoxia increased
the phosphorylation of PDH at sites 1, 2, and 3 compared to
normoxic controls (Fig. 1).

Fig. 2 a Western blot analysis of the effect of 100 μM CoCl2 on
HepG2 cells across the indicated time course. Amounts of HIF-1α, the
phosphorylation state of PDH site 1 (E1α subunit, phosphoserine293) and
the β-actin loading control are shown. b Western blot analysis of NIH/
3T3 fibroblasts that were incubated with the indicated concentrations of
CoCl2 or exposed to hypoxia (H; 1 % O2) for 24 h. The phosphorylation
state of PDH site 1 (E1α subunit, phosphoserine293) and β-actin loading
control are indicated. c Western blot analysis of J774 macrophages that
were incubated with the indicated concentrations of CoCl2 or exposed to
hypoxia (“H”; 1 % O2) for 24 h. The phosphorylation state of
PDH site 1 (E1α subunit, phosphoserine293) and β-actin loading
control are shown

CoCl2 decreases phosphorylation of E1α in NIH/3T3
fibroblasts and J774 macrophages
In order to test whether or not the CoCl2 effect on
HepG2 cells was cell line-specific, NIH/3T3 mouse
fibroblasts and J774 mouse macrophages were exposed
to CoCl2 for 24 h. The viability of these fibroblasts and
macrophages was significantly reduced at CoCl2 concentrations above 300 and 150 μM, respectively, and
thus exposures used were lowered accordingly. Nevertheless, just as in the HepG2 cells, both NIH/3T3
(Fig. 2b) and J774 cells (Fig. 2c) showed a significant
decrease in the phosphorylation of site 1, but at even
lower concentrations (25 μM CoCl2).
Desferrioxamine and DMOG increase HIF-1α
but desferrioxamine has little effect on PDH
phosphorylation in HepG2 cells
Desferrioxamine is an iron chelator that likely inhibits
PHD in a similar fashion as CoCl2, eliminating the functionally necessary ferrous iron of PHD, thereby stabilizing
HIF-1α (Wang and Semenza 1993a; Pugh et al. 1997;
Ivan et al. 2001; Jaakkola et al. 2001). DMOG is
membrane-permeable competitive inhibitor of PHD (Jaakkola
et al. 2001). In order to test whether the CoCl2 effect on PDH
was specific to that compound, HepG2 cells were incubated
with desferrioxamine or DMOG for 24 h. As expected, both
desferrioxamine and DMOG increased the levels of HIF-1α in
a dose-dependent manner, and desferrioxamine increased the
levels of HIF-1α above that seen with hypoxia, similar to
CoCl2 (Fig. 3). But, in contrast to expectations, desferrioxamine did not increase the phosphorylation of PDH at site
1 or site 3, and only marginally increased site 2 phosphorylation even in the face of strongly elevated HIF-1α
(Fig. 3a). DMOG, meanwhile, did increase phosphorylation of all 3 sites, although it did not elevate the levels of
HIF-1α to the extent of CoCl 2 or desferrioxamine
(Fig. 3b). DMOG did not increase the phosphorylation
of all 3 sites to the degree that hypoxia did, but the levels
of HIF-1α were also lower than under hypoxia (Fig. 3b).
Thus, while CoCl2 and desferrioxamine increased HIF-1α,
neither of these compounds promoted the anticipated
increase in PDH phosphorylation, and CoCl2 actually
decreased it. DMOG did elevate HIF-1α and PDH
phosphorylation to a degree, but failed to promote the
stronger effects seen with the natural state of hypoxia
(Fig. 3b). Quantification of the Western blots illustrates
the influence on HIF-1α and the phosphorylation state
of PDH of CoCl2 and desferrioxamine (Fig. 4) and
DMOG (Fig. 5). Taken together, our results indicate
that CoCl2 and desferrioxamine are unreliable mimics
of hypoxia for events downstream of HIF-1α.
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Fig. 3 a Western blot analysis of HepG2 cells that were incubated with the
indicated concentrations of desferrioxamine or exposed to hypoxia (H; 1 %
O2) for 24 h. Amounts of HIF-1α, the phosphorylation state of PDH site 1
(E1α subunit, phosphoserine293), site 2 (E1α subunit, phosphoserine300),
site 3 (E1α subunit, phosphoserine232) and the β-actin loading control are
documented. b Western blot analysis of HepG2 cells that were incubated
with the indicated concentrations of DMOG or exposed to hypoxia
(“H”; 1 % O2) for 24 h. Amounts of HIF-1α, the phosphorylation
state of PDH site 1 (E1α subunit, phosphoserine293), site 2 (E1α
subunit, phosphoserine300), site 3 (E1α subunit, phosphoserine232),
and the β-actin loading control are shown

CoCl2 reduces mRNA expression of PDK-2
We predicted that the decrease in PDH phosphorylation
observed when cells were incubated with CoCl2 was
promoted by a decrease in the synthesis of PDK-2, the
most abundant PDK isoform in liver cells (BowkerKinley et al. 1998; Korotchkina and Patel 2001). We
tested this hypothesis qualitatively using PCR and found
that mRNA for PDK-2 in HepG2 cells did appear to
decrease when the cells were incubated with CoCl2,
while cells exposed to 24 h of hypoxia showed little
difference in mRNA compared to normoxic controls
(Fig. 6a). mRNA for PDK-1 and PDK-4 did not differ
in cells incubated with CoCl2 versus untreated controls
or cells exposed to hypoxia, and PDK-3 mRNA

increased in both hypoxic cells and CoCl2-treated cells,
as expected (data not shown). We used rtqPCR analysis
to confirm that PDK-2 mRNA quantitatively declined in
response to CoCl 2 exposure. At concentrations of
250 μM CoCl2 and above, PDK-2 mRNA exhibited a
statistically significant drop of 65–80 % compared to untreated
control cells (Fig. 6b). PDK-2 mRNA expression was
normalized to the mRNA of a housekeeper gene (β-actin).
Thus, CoCl2 may have decreased PDH phosphorylation
by decreasing the expression of PDK-2 mRNA (Fig. 6). A
drop in the amount of PDK-2 would disrupt the balance
between this kinase and PDH phosphatase, thereby lowering
the steady-state phosphorylation of PDH. The effect of
CoCl2 on PDK-2 is surprising because previous work has
shown that when HIF-1α is stabilized by hypoxia the
expression of PDK-1 and PDK-3 mRNA increases (Kim
et al. 2006; Papandreou et al. 2006; Semenza 2007; Lu
et al. 2008). Due to our interest in HepG2 cells, PDK-2
was investigated in the present study because of its
prominence in liver tissue (Bowker-Kinley et al. 1998;
Korotchkina and Patel 2001). Information regarding the
hypoxia responsiveness of PDK-2 is very limited, but it
is appropriate to note that Lu et al. (2008) reported a
low-scoring HRE associated with the PDK-2 gene. They
observed no increase in expression of PDK-2 mRNA
after exposure to hypoxia, a result they conjectured was
due to cell type (HeLa cells). In this study, we showed
that hypoxia does not increase the PDK-2 mRNA level
in HepG2 cells. Thus, the increased levels of PDH
phosphorylation observed under hypoxia are likely the
result of increased PDK-3 synthesis, based upon the
unchanged expression of PDK-1 and PDK-4 mRNA
under hypoxia mentioned above for HepG2 cells.
Concluding remarks
Adaptation to hypoxia in mammalian cells has become an
important topic in cancer research and metabolic preconditioning in many tissues and organs. Some cancers utilize the
cellular hypoxia response within the tumor microenvironment
when rapid cell growth has outpaced adequate vascularization
and even afterwards to keep mitochondrial activity low
(Vander Heiden et al. 2009; Ježek et al. 2010; Semenza
2010; Jose et al. 2011). The response to hypoxia in
mammalian cells commonly involves the depression of
mitochondrial oxidative phosphorylation and enhanced
glycolytic poise. We originally intended to increase levels of
HIF-1α with CoCl2 (or desferrioxamine, DMOG) in order to
test the hypothesis that fostering such a shift in metabolic
poise would precondition mammalian cells (Menze et al.
2005, 2010; Hand et al. 2011a; Semenza 2011) for increased
survivorship during biostabilization by cryopreservation and
desiccation (Menze et al. 2010; Hand et al. 2011b). However,
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Fig. 4 Quantitative impact of
24 h incubations of HepG2 cells
with CoCl2 (solid lines) and
desferrioxamine (dashed lines)
on the phosphorylation states of
PDH site 1 (closed circles), site
2 (closed squares) and site 3
(closed triangles). All values
are normalized to β-actin.
Slopes of the linear regressions
for sites 1 and 3 were not
significantly different from zero
(p>0.05) for the HepG2 cells
incubated with desferrioxamine,
while the small positive slope for
site 2 was significantly different
from zero (p00.013). Inset Elevation of HIF-1α (normalized to
β-actin) in HepG2 cells after
24 h exposures to CoCl2 (open
circles) and desferrioxamine
(open squares)

the major observation of this study is the unexpected and
prominent decrease in PDH phosphorylation when cells are
incubated with CoCl2 compared to the increase in PDH
phosphorylation under hypoxia despite the significant
increase of HIF-1α in both cases. We surmise that the
cause of this decrease is the significantly lower levels of
PDK-2 transcription for cells incubated with CoCl2
Fig. 5 Quantification of
Western blots illustrates the
impact of 24 h incubation with
DMOG on the phosphorylation
states of PDH site 1 (circles),
site 2 (squares), and site 3
(triangles) in HepG2 cells. All
values are normalized to βactin. Inset Elevation of HIF-1α
(normalized to β-actin) in
HepG2 cells after 24 h exposures
to DMOG

compared to those under hypoxia. The mechanism behind
the surprising impact of CoCl2 on PDK-2 expression is as
yet unknown and warrants further study. But it is clear from
our results that CoCl2 is a poor choice to artificially mimic
hypoxia in HepG2, NIH/3T3, and J774 cell lines for selected
events downstream of HIF-1α stabilization. Similarly, we also
show that desferrioxamine does not promote the expected
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Fig. 6 Expression of PDK-2 mRNA in HepG2 cells that were incubated
with the indicated concentrations of CoCl2 or exposed to hypoxia (H; 1 %
O2) for 24 h. a PCR analyses of mRNA for PDK-2 and β-actin (loading
control) are shown. b Results obtained by rtqPCR. PDK-2 mRNA was
normalized to a housekeeper gene (β-actin mRNA) and expressed as a
percentage of the untreated/normoxic control. Asterisks indicate
significant differences from the hypoxia treatment (H) (one-way
ANOVA, n09, mean ± 1SD; p≤0.05)

increase in PDH phosphorylation levels seen under hypoxia in
HepG2 cells, making it an unsuitable mimic of hypoxia as
well. While it does increase HIF-1α and PDH phosphorylation,
DMOG was significantly less effective than hypoxia. The
observations reported in this paper emphasize the diligence
required when attempts are made to artificially stimulate a
physiological state with drugs that actually may promote
unwanted, divergent effects or have little or no impact.
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